Nondeficit Schizophrenic Patients Research Articles

Improved Multiclassification of Schizophrenia Based on Xgboost and Information Fusion for Small Datasets.

To improve the performance in multiclass classification for small datasets, a new approach for schizophrenic classification is proposed in the present study. Firstly, the Xgboost classifier is introduced to discriminate the two subtypes of schizophrenia from health controls by analyzing the functional magnetic resonance imaging (fMRI) data, while the gray matter volume (GMV) and amplitude of low-frequency fluctuations (ALFF) are extracted as the features of classifiers. Then, the D-S combination rule of evidence is used to achieve fusion to determine the basic probability assignment based on the output of different classifiers. Finally, the algorithm is applied to classify 38 healthy controls, 16 deficit schizophrenic patients, and 31 nondeficit schizophrenic patients. 10-folds cross-validation method is used to assess classification performance. The results show the proposed algorithm with a sensitivity of 73.89%, which is higher than other classification algorithms, such as supported vector machine (SVM), logistic regression (LR), K-nearest neighbor (KNN) algorithm, random forest (RF), BP neural network (NN), classification and regression tree (CART), naive Bayes classifier (NB), extreme gradient boosting (Xgboost), and deep neural network (DNN). The accuracy of the fusion algorithm is higher than that of classifier based on the GMV or ALFF in the small datasets. The accuracy rate of the improved multiclassification method based on Xgboost and fusion algorithm is higher than that of other machine learning methods, which can further assist the diagnosis of clinical schizophrenia.

Deficit Schizophrenia Is Characterized by Defects in IgM-Mediated Responses to Tryptophan Catabolites (TRYCATs): a Paradigm Shift Towards Defects in Natural Self-Regulatory Immune Responses Coupled with Mucosa-Derived TRYCAT Pathway Activation.

Deficit schizophrenia is accompanied by mucosa-associated activation of the tryptophan catabolite (TRYCAT) pathway, as indicated by increased IgA responses to noxious (NOX) TRYCATs, but not regulatory or protective (PRO) TRYCATs, suggesting increased neurotoxic, excitotoxic, inflammatory, and oxidative potential. No previous studies examined IgM-mediated autoimmune responses to the TRYCAT pathway in deficit versus nondeficit schizophrenia. We measured IgM responses to NOX TRYCATs, namely, quinolinic acid (QA), 3-OH-kynurenine (3HK), picolinic acid (PA), and xanthurenic (XA) acid, and PRO TRYCATs, including kynurenic acid (KA) and anthranilic acid (AA), in 40 healthy controls and 40 deficit and 40 nondeficit schizophrenic patients. We computed the IgM responses to NOX (QA + PA + 3HK + XA)/PRO (AA + KA) ratio and ∆ differences in IgA - IgM TRYCAT values and NOX/PRO ratio. Deficit schizophrenia is characterized by significantly attenuated IgM responses to all TRYCATs and NOX/PRO ratio and highly increased ∆IgA - IgM NOX/PRO ratio as compared to nondeficit schizophrenia and healthy controls. The negative symptoms of schizophrenia are significantly and positively associated with increased IgM responses directed against the KA/3HK ratio and ∆IgA - IgM NOX/PRO ratio. The findings support the view that deficit schizophrenia is a distinct subtype of schizophrenia that may be significantly discriminated from nondeficit schizophrenia. Deficit schizophrenia is accompanied by a highly specific defect in IgM isotype-mediated regulatory responses directed to the TRYCAT pathway. Lowered IgM regulatory responses together with mucosa-derived activation of the TRYCAT pathway may contribute to neuroprogression, negative symptoms, and deficit schizophrenia. All in all, a highly specific defect in the compensatory (anti-)inflammatory reflex system (CIRS), namely, natural IgM-mediated regulatory responses, may underpin deficit schizophrenia.

Neurological soft signs as an endophenotype in siblings of deficit versus nondeficit schizophrenic patients

BackgroundDeficit schizophrenia affects 25–30% of chronic schizophrenic patients. Endophenotypes are quantifiable biological variations that are types of stable trait markers of presumed inherited vulnerability to a disease. Neurological soft signs (NSS) are important endophenotypes of schizophrenia

Gray matter volumedifferences in deficit and nondeficit schizophrenia:a voxel-based morphometric study

：Objective To examine thedifferences in the structure of brain white matter among deficit schizophrenia, nondeficitschizophrenia and healthy controls by using voxel-based morphometry (VBM). Methods Tendeficit schizophrenic patients, eleven nondeficit patients and fifteen healthy comparisonsubjects participated in the study. All the subjects were scanned by GE Twin Speed 1.5TMRI system. Whole brain, voxel-wise analyses of regional white matter volume wereconducted by the VBM toolbox on the Matlab7.6 and SPM5. t -test was then used for thecomparison between groups. Results Compared to the healthy controls, nondeficitschizophrenic patients significantly decreased the density of gray matter in the frontal,parietal, temporal, occipital lobe and basal ganglia , while the deficit patients showedthe characteristically broad and significant decreasion in the frontal lobe, includingleft medial frontal gyrus, bilateral inferior frontal gyrus, left middle frontal gyrus,and left orbital gyrus (Cluster ≥ 30 mm3, P<0.01). Moreover,deficit patients showed the decreasion in the temporal cortex and the limbic lobe (rightinsula). Relative to the nondeficit schizophrenic patients, deficit patients hadsignificant regional gray matter decreases in the left medial frontal gyrus, bilateralinferior frontal gyrus, right precentral gyrus, and right superior temporal gyrus (Cluster≥ 30 mm3, P<0.01).Conclusion Structural heterogeneity in schizophrenia may relate to specific patterns ofgray matter density reductions in deficit and nondeficit patient. However the two subtypeof schizophremia patients share a common prefrontal-temperal pattern of structural brainalterations. Key words: Deficit schizophrenia; Magnetic resonanceimaging; Voxel-based morphometry; Cray matter

The subjective quality of life in deficit and nondeficit schizophrenic patients

We assessed the subjective quality of life (QOL) of 30 deficit schizophrenic patients compared to 112 nondeficit schizophrenic patients. The deficit patients did not differ in term of QOL, total score of positive symptoms, general psychopathology from the nondeficit patients. This result suggested an absence of impact of primary negative symptoms on the subjective QOL in schizophrenic patients.

Reexamination of the characteristics of the deficit schizophrenia patients

The aim of this study was to reexamine and compare the characteristics of the deficit and nondeficit schizophrenic patients. This cross-sectional study consisted of 62 in- and out-patients, 18-65 years of age, diagnosed with schizophrenia according to DSM-IV. The sociodemographic variables, premorbid adjustment, clinical course and general functioning level in the past five years were evaluated by utilizing the appropriate sections of Comprehensive Assessment of Symptoms and History (CASH). In addition, GAF, the Schedule for the Deficit Syndrome (SDS), Positive and Negative Syndrome Scale (PANSS), Montgomery Asberg Depression Scale (MADRS), the Neurological Evaluation Scale (NES) and the Simpson Angus Extrapyramidal Side Effects (EPS) Rating Scale, Trail A and B, Verbal Fluency, Stroop, Block Design and Finger Tapper tests were administered. Using the SDS, 19 patients (30.6 %) were categorized as deficit; 43 (69.4 %) were categorized as nondeficit. The deficit patients were worse on the Functioning During Past Five Years score of CASH. The PANSS and MADRS mean scores were not significantly different between the two groups, except a higher level of negative symptoms observed in the deficit group. NES scores were also significantly higher in the deficit group. However, sociodemographic and other clinical variables, neurocognitive measures and EPS symptoms did not show any significant difference between the two groups. Our findings suggest that the deficit schizophrenia is a distinct subgroup comprised of patients who have more negative symptoms, neurological impairment and poor functioning which may have a common underlying pathology.

A Tc-99m HMPAO SPECT study of regional cerebral blood flow in drug-free schizophrenic patients with deficit and non-deficit syndrome

Twenty-nine patients with DSM-IV diagnoses of schizophrenia were categorized into deficit syndrome ( n=14) and non-deficit syndrome ( n=15) subgroups on the basis of the Schedule for the Deficit Syndrome. The patients, who had all been free of antipsychotic medication for at least 3 weeks, and 17 sex- and age-matched normal controls were studied with single-photon emission computed tomography with Tc-99m HMPAO. Age at onset, Brief Psychiatric Rating Scale (BPRS) total scores, BPRS positive symptom subscores and duration of illness were similar between the two schizophrenic subgroups. As expected, the deficit patients had more negative symptoms than the non-deficit patients. There were no statistically significant correlations between clinical parameters and regional cerebral blood flow (rCBF) values. The deficit syndrome subgroup showed diminished rCBF in the frontal regions bilaterally, right parietal regions and right superior temporal region compared with the control groups. Deficit patients showed significantly lower rCBF perfusion ratios in the right superior and inferior frontal cortex than did the non-deficit patients. No differences were detected between the controls and the non-deficit schizophrenic patients in terms of rCBF perfusion indices. The results of the present study confirm previous reports of different patterns of rCBF in deficit vs. non-deficit schizophrenic subgroups.

Regional cerebral blood flow in deficit/nondeficit types of schizophrenia according to SDS criteria

A relationship between “hypofrontality” and a negative form of schizophrenia is commonly found. The Schedule for the Deficit Syndrome (SDS) provides specific criteria for assessing the presence of negative symptoms, their duration and whether the symptoms are primary or secondary. The purpose of our study was to compare the regional cerebral blood flow (rCBF) at rest, in 62 deficit and nondeficit schizophrenic patients, according to the SDS criteria (French version). The deficit patients in our population were comparable to those described in the literature (stability of their negative symptoms with time, poor premorbid adjustment, duration of the illness, age at the first episode, etc.). No difference was found in the locoregional perfusion with respect to the DSM-III-R type of schizophrenia, the sex or the type of treatment received. The patients with a deficit form of schizophrenia showed a significant bilateral reduction in single photon emission computed tomography (SPECT) perfusion in the right frontodorsolateral cortex ( P=.0105) and the left frontodorsolateral cortex ( P=.0004) compared with the nondeficit schizophrenic patients. The contribution of SDS seems to be helpful in distinguishing between significant cerebral characteristics in deficit schizophrenics, as defined by Carpenter. These results suggest a decrease in prefrontal perfusion at rest, which corresponds with neuropsychological data.

A 99mTC HMPAO SPECT study of regional cerebral blood flow in olanzapine-treated deficit and nondeficit schizophrenic patients

A 99mTC HMPAO SPECT study of regional cerebral blood flow in olanzapine-treated deficit and nondeficit schizophrenic patients

Month of birth in deficit and non-deficit schizophrenic patients

In order to test the hypothesis that an excess of summer births is a risk factor for deficit syndrome, the month of birth was studied in 53 deficit schizophrenic patients compared to 158 non-deficit patients. No significant difference in terms of month of birth or season of birth was observed between deficit and non-deficit patients, suggesting that summer births might not be a risk factor for deficit schizophrenia.

Plasma 3-Methoxy-4-Hydroxyphenylglycol and Homovanillic Acid Measurements in Deficit and Nondeficit Forms of Schizophrenia

Background: Discrepancies in the biochemical research on negative symptoms in schizophrenia may be ascribed to the lack of differentiation into primary and secondary negative symptoms. We have used Carpenter’s criteria to define the deficit syndrome of schizophrenia as the presence of enduring and primary negative symptoms and measured catecholaminergic parameters in deficit as compared with nondeficit schizophrenics. Methods: We have investigated plasma homovanillic acid (pHVA) and 3-methoxy-4-hydroxyphenylglycol (pMHPG) concentrations in 34 DSM-III-R neuroleptic-treated schizophrenic patients who were classified into deficit ( n = 14) and nondeficit ( n = 20) forms of schizophrenia. All these patients were in a stable clinical and therapeutic status for the preceding 12 months. Results: The 14 deficit schizophrenic patients had lower plasma levels of pHVA and higher plasma concentrations of pMHPG from 9 am to 12 am as compared with the 20 nondeficit schizophrenic patients. The two groups did not differ on any demographic, therapeutic, or clinical variable considered. Conclusions: Our data are consistent with the postulated distinct pathophysiological basis for the deficit syndrome of schizophrenia and suggest that opposite alterations in the pHVA or pMHPG levels may reflect specific changes in noradrenergic and dopaminergic functions in these deficit patients.

65-157 - Depressive symptoms in deficit and nondeficit schizophrenic patients

65-157 - Depressive symptoms in deficit and nondeficit schizophrenic patients

Drug abuse among deficit and nondeficit schizophrenic patients in the DSM-IV field trials

Drug abuse among deficit and nondeficit schizophrenic patients in the DSM-IV field trials

Glucose metabolism in deficit and non-deficit schizophrenic patients

We retrospectively collected three patients with clinically mild encephalitis with a reversible splenial lesion (MERS) after mumps vaccination, and reviewed five patients, including two patients previously reported. The five patients (all males, aged 1 to 9) presented with fever, vomiting, or headache as the initial symptoms (day 0), suggesting meningitis, at 13 to 21 days after mumps vaccination. Consciousness disturbance, delirious behavior, seizures, or dysarthria was observed on days 1 to 3, which had completely resolved before day 11. Hyponatremia was observed in all patients. A cerebrospinal fluid study showed pleocytosis, and confirmed the vaccine strain genome. MRI revealed reduced diffusion in the splenium of the corpus callosum on days 2 to 4, which had completely disappeared on the follow-up studies performed on days 7–15. EEG showed high voltage slow wave in three patients, which later normalized. These findings led to a diagnosis of MERS after mumps vaccination. MERS after mumps vaccination may be more common than previously considered. MERS is suspected when a male patient after mumps vaccination presents with neurological symptoms with hyponatremia, following symptoms of aseptic meningitis, and MRI would be performed to examine the splenium of the corpus callosum.